1. Executive Summary |
2. Lung Cancer Market Introduction |
2.1. Lung Cancer Market Taxonomy |
2.2. Lung Cancer Market Definitions |
2.2.1. Diagnostics Method |
2.2.2. Type |
2.2.3. Treatment |
2.2.4. Distribution Channel |
2.2.5. Region |
3. Lung Cancer Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Lung Cancer Market Dynamic Factors - Impact Analysis |
3.6. Impact of COVID-19 on The Market |
3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic |
3.8. Mapping Market Players Activities |
3.9. Recent Key Developments |
3.10. Financial Status of the Market Players |
3.11. Recent Acquisitions, Collaborations, and Mergers |
4. Lung Cancer Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Lung Cancer Market Forecast, Diagnostics Method, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
5.1. Chest X-ray |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. CT scan |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. 18F-FDG PET scanning |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Bronchoscopy |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Endobronchial Biopsy Scan (EBUS) |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Biopsy |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6. Lung Cancer Market Forecast, Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
6.1. Small Cell Lung Cancer |
6.1.1. Small cell carcinoma (oat cell cancer). |
6.1.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.1.3. Market Opportunity Analysis |
6.1.2. Combined small cell carcinoma. |
6.1.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.2.3. Market Opportunity Analysis |
6.2. Non-small Cell lung Cancer |
6.2.1. Squamous cell carcinoma |
6.2.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.1.3. Market Opportunity Analysis |
6.2.2. Large cell carcinoma |
6.2.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
6.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.2.3. Market Opportunity Analysis |
6.2.3. Adenocarcinoma |
6.2.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3.3. Market Opportunity Analysis |
6.2.4. Others |
6.2.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
6.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.4.3. Market Opportunity Analysis |
7. Market Opportunity Analysis Lung Cancer Market Forecast, Treatment, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.1. Surgery |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Chemotherapy |
7.2.1. Vinca Alkaloids |
7.2.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.1.3. Market Opportunity Analysis |
7.2.2. Antimetabolites |
7.2.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.2.3. Market Opportunity Analysis |
7.2.3. Taxanes |
7.2.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3.3. Market Opportunity Analysis |
7.2.4. Podophyllotoxin Derivatives |
7.2.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.4.3. Market Opportunity Analysis |
7.2.5. Platinum-Containing Compounds |
7.2.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.5.3. Market Opportunity Analysis |
7.2.6. Antifolate Antineoplastic Agents |
7.2.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.6.3. Market Opportunity Analysis |
7.3. Immunotherapy |
7.3.1. PD-1/PD-L1 inhibitors |
7.3.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.1.3. Market Opportunity Analysis |
7.3.2. CTLA-4 inhibitor |
7.3.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.2.3. Market Opportunity Analysis |
7.3.3. Others |
7.3.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3.3. Market Opportunity Analysis |
7.4. Targeted Therapy |
7.4.1. Angiogenesis Inhibitors |
7.4.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.1.3. Market Opportunity Analysis |
7.4.2. KRAS inhibitor |
7.4.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.2.3. Market Opportunity Analysis |
7.4.3. KRAS inhibitor |
7.4.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3.3. Market Opportunity Analysis |
7.4.4. EGFR inhibitors |
7.4.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.4.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.4.3. Market Opportunity Analysis |
7.4.5. ALK inhibitors |
7.4.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.4.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.5.3. Market Opportunity Analysis |
7.5. Radiation Therapy |
7.5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
7.5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.1.3. Market Opportunity Analysis |
8. Market Opportunity Analysis Lung Cancer Market Forecast, Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
8.1. Hospital Pharmacy |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacy |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacy |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Lung Cancer Market Forecast, Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Lung Cancer Market - Opportunity Analysis Index, Diagnostics Method, Type, Treatment, Distribution Channel, and Region, 2024 - 2030 |
10. North America Lung Cancer Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
10.1. Diagnostics Method Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
10.1.1. Chest X-ray |
10.1.2. Cytoscopy |
10.1.3. 18F-FDG PET scanning |
10.1.4. Bronchoscopy |
10.1.5. Endobronchial Biopsy Scan (EBUS) |
10.1.6. Biopsy |
10.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Non Non-small Cell lung Cancer |
10.2.1.1. Small cell carcinoma (oat cell cancer). |
10.2.1.2. Combined small cell carcinoma. |
10.2.2. Non-small Cell lung Cancer |
10.2.2.1. Squamous cell carcinoma |
10.2.2.2. Large cell carcinoma |
10.2.2.3. Adenocarcinoma |
10.2.2.4. Others |
10.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Surgery |
10.3.2. Chemotherapy |
10.3.2.1. Platinum Containing Compound |
10.3.2.2. Taxanes |
10.3.2.3. Antimetabolites |
10.3.2.4. vinca alkaloids |
10.3.2.5. podophyllotoxin derivatives |
10.3.2.6. antifolate antineoplastic agents |
10.3.3. Immunotherapy |
10.3.3.1. PD-1/PD-L1 inhibitors |
10.3.3.2. CTLA-4 inhibitor |
10.3.3.3. Others |
10.3.4. Targeted Therapy |
10.3.4.1. angiogenesis inhibitors |
10.3.4.2. KRAS inhibitor |
10.3.4.3. EGFR inhibitors |
10.3.4.4. ALK inhibitors |
10.3.4.5. Others |
10.3.5. Radiation Therapy |
10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Hospital Pharmacy |
10.4.2. Retail Pharmacy |
10.4.3. Online Pharmacy |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
10.5.1. U.S. |
10.5.2. Canada |
10.6. North America Lung Cancer Market - Opportunity Analysis Index, Diagnostics Method, Type, Treatment, Distribution Channel and Country, 2024 - 2030 |
10.7. North America Lung Cancer Market Dynamics Trends |
11. Europe Lung Cancer Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
11.1. Diagnostics Method Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
11.1.1. Chest X-ray |
11.1.2. Cytoscopy |
11.1.3. 18F-FDG PET scanning |
11.1.4. Bronchoscopy |
11.1.5. Endobronchial Biopsy Scan (EBUS) |
11.1.6. Biopsy |
11.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Non Non-small Cell lung Cancer |
11.2.1.1. Small cell carcinoma (oat cell cancer). |
11.2.1.2. Combined small cell carcinoma. |
11.2.2. Non-small Cell lung Cancer |
11.2.2.1. Squamous cell carcinoma |
11.2.2.2. Large cell carcinoma |
11.2.2.3. Adenocarcinoma |
11.2.2.4. Others |
11.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Surgery |
11.3.2. Chemotherapy |
11.3.2.1. Platinum Containing Compound |
11.3.2.2. Taxanes |
11.3.2.3. Antimetabolites |
11.3.2.4. vinca alkaloids |
11.3.2.5. podophyllotoxin derivatives |
11.3.2.6. antifolate antineoplastic agents |
11.3.3. Immunotherapy |
11.3.3.1. PD-1/PD-L1 inhibitors |
11.3.3.2. CTLA-4 inhibitor |
11.3.3.3. Others |
11.3.4. Targeted Therapy |
11.3.4.1. angiogenesis inhibitors |
11.3.4.2. KRAS inhibitor |
11.3.4.3. EGFR inhibitors |
11.3.4.4. ALK inhibitors |
11.3.4.5. Others |
11.3.5. Radiation Therapy |
11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Hospital Pharmacy |
11.4.2. Retail Pharmacy |
11.4.3. Online Pharmacy |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Germany |
11.5.2. UK |
11.5.3. France |
11.5.4. Italy |
11.5.5. Spain |
11.5.6. Rest of Europe |
11.6. Europe Lung Cancer Market - Opportunity Analysis Index, Diagnostics Method, Type, Treatment, Distribution Channel and Country, 2024 - 2030 |
11.7. Europe Lung Cancer Market Dynamics Trends |
12. Asia-Pacific Lung Cancer Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
12.1. Diagnostics Method Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
12.1.1. Chest X-ray |
12.1.2. Cytoscopy |
12.1.3. 18F-FDG PET scanning |
12.1.4. Bronchoscopy |
12.1.5. Endobronchial Biopsy Scan (EBUS) |
12.1.6. Biopsy |
12.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Non Non-small Cell lung Cancer |
12.2.1.1. Small cell carcinoma (oat cell cancer). |
12.2.1.2. Combined small cell carcinoma. |
12.2.2. Non-small Cell lung Cancer |
12.2.2.1. Squamous cell carcinoma |
12.2.2.2. Large cell carcinoma |
12.2.2.3. Adenocarcinoma |
12.2.2.4. Others |
12.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Surgery |
12.3.2. Chemotherapy |
12.3.2.1. Platinum Containing Compound |
12.3.2.2. Taxanes |
12.3.2.3. Antimetabolites |
12.3.2.4. vinca alkaloids |
12.3.2.5. podophyllotoxin derivatives |
12.3.2.6. antifolate antineoplastic agents |
12.3.3. Immunotherapy |
12.3.3.1. PD-1/PD-L1 inhibitors |
12.3.3.2. CTLA-4 inhibitor |
12.3.3.3. Others |
12.3.4. Targeted Therapy |
12.3.4.1. angiogenesis inhibitors |
12.3.4.2. KRAS inhibitor |
12.3.4.3. EGFR inhibitors |
12.3.4.4. ALK inhibitors |
12.3.4.5. Others |
12.3.5. Radiation Therapy |
12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Hospital Pharmacy |
12.4.2. Retail Pharmacy |
12.4.3. Online Pharmacy |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
12.5.1. Japan |
12.5.2. China |
12.5.3. India |
12.5.4. ASEAN |
12.5.5. Rest of Asia-Pacific |
12.6. Asia-Pacific Lung Cancer Market - Opportunity Analysis Index, Diagnostics Method, Type, Treatment, Distribution Channel and Country, 2024 - 2030 |
12.7. Asia-Pacific Lung Cancer Market Dynamics Trends |
13. Latin America Lung Cancer Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
13.1. Diagnostics Method Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
13.1.1. Chest X-ray |
13.1.2. Cytoscopy |
13.1.3. 18F-FDG PET scanning |
13.1.4. Bronchoscopy |
13.1.5. Endobronchial Biopsy Scan (EBUS) |
13.1.6. Biopsy |
13.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
13.2.1. Non Non-small Cell lung Cancer |
13.2.1.1. Small cell carcinoma (oat cell cancer). |
13.2.1.2. Combined small cell carcinoma. |
13.2.2. Non-small Cell lung Cancer |
13.2.2.1. Squamous cell carcinoma |
13.2.2.2. Large cell carcinoma |
13.2.2.3. Adenocarcinoma |
13.2.2.4. Others |
13.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Surgery |
13.3.2. Chemotherapy |
13.3.2.1. Platinum Containing Compound |
13.3.2.2. Taxanes |
13.3.2.3. Antimetabolites |
13.3.2.4. vinca alkaloids |
13.3.2.5. podophyllotoxin derivatives |
13.3.2.6. antifolate antineoplastic agents |
13.3.3. Immunotherapy |
13.3.3.1. PD-1/PD-L1 inhibitors |
13.3.3.2. CTLA-4 inhibitor |
13.3.3.3. Others |
13.3.4. Targeted Therapy |
13.3.4.1. angiogenesis inhibitors |
13.3.4.2. KRAS inhibitor |
13.3.4.3. EGFR inhibitors |
13.3.4.4. ALK inhibitors |
13.3.4.5. Others |
13.3.5. Radiation Therapy |
13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Hospital Pharmacy |
13.4.2. Retail Pharmacy |
13.4.3. Online Pharmacy |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Brazil |
13.5.2. Argentina |
13.5.3. Rest of Latin America |
13.6. Latin America Lung Cancer Market - Opportunity Analysis Index, Diagnostics Method, Type, Treatment, Distribution Channel and Country, 2024 - 2030 |
13.7. Latin America Lung Cancer Market Dynamics Trends |
14. Middle East and Africa Lung Cancer Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million) |
14.1. Diagnostics Method Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
14.1.1. Chest X-ray |
14.1.2. Cytoscopy |
14.1.3. 18F-FDG PET scanning |
14.1.4. Bronchoscopy |
14.1.5. Endobronchial Biopsy Scan (EBUS) |
14.1.6. Biopsy |
14.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
14.2.1. Non Non-small Cell lung Cancer |
14.2.1.1. Small cell carcinoma (oat cell cancer). |
14.2.1.2. Combined small cell carcinoma. |
14.2.2. Non-small Cell lung Cancer |
14.2.2.1. Squamous cell carcinoma |
14.2.2.2. Large cell carcinoma |
14.2.2.3. Adenocarcinoma |
14.2.2.4. Others |
14.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
14.3.1. Surgery |
14.3.2. Chemotherapy |
14.3.2.1. Platinum Containing Compound |
14.3.2.2. Taxanes |
14.3.2.3. Antimetabolites |
14.3.2.4. vinca alkaloids |
14.3.2.5. podophyllotoxin derivatives |
14.3.2.6. antifolate antineoplastic agents |
14.3.3. Immunotherapy |
14.3.3.1. PD-1/PD-L1 inhibitors |
14.3.3.2. CTLA-4 inhibitor |
14.3.3.3. Others |
14.3.4. Targeted Therapy |
14.3.4.1. angiogenesis inhibitors |
14.3.4.2. KRAS inhibitor |
14.3.4.3. EGFR inhibitors |
14.3.4.4. ALK inhibitors |
14.3.4.5. Others |
14.3.5. Radiation Therapy |
14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%) |
14.4.1. Hospital Pharmacy |
14.4.2. Retail Pharmacy |
14.4.3. Online Pharmacy |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Saudi Arabia |
14.5.2. GCC Countries |
14.5.3. South Africa |
14.5.4. Rest of MEA |
14.6. MEA Lung Cancer Market - Opportunity Analysis Index, Diagnostics Method, Type, Treatment, Distribution Channel and Country, 2024 - 2030 |
14.7. MEA Lung Cancer Market Dynamics Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, Diagnostics Method Offerings, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. Genentech (F. Hoffmann-La Roche Ltd) |
15.2.2. Eli Lilly and Company |
15.2.3. Celgene Corporation |
15.2.4. AstraZeneca |
15.2.5. Pfizer Inc. |
15.2.6. Sanofi |
15.2.7. Novartis AG |
15.2.8. Astellas |
15.2.9. Bristol Myers Squibb |
15.2.10. Boehringer Ingelheim Pharmaceuticals, Inc. |
15.2.11. Millennium Pharmaceuticals, Inc. |
15.2.12. Merck Sharp & Dohme Corp. |
16. Research Methodology |
17. Key Assumptions and Acronyms |
2021 is the base year and 2028 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.